Michael Conick Hanley
Director de Operaciones en ALTO NEUROSCIENCE, INC. .
Fortuna: 50 608 $ al 31/05/2024
Cargos activos de Michael Conick Hanley
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ALTO NEUROSCIENCE, INC. | Director de Operaciones | 20/05/2024 | - |
Historial de carrera de Michael Conick Hanley
Antiguos cargos conocidos de Michael Conick Hanley.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SPYRE THERAPEUTICS, INC. | Corporate Officer/Principal | 04/11/2019 | 14/04/2023 |
Esteve Pharmaceuticals S.A.
 Esteve Pharmaceuticals S.A. Pharmaceuticals: OtherHealth Technology Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain. | Corporate Officer/Principal | 01/04/2018 | 01/09/2019 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Ventas & Marketing | 01/07/2015 | 01/06/2017 |
Formación de Michael Conick Hanley.
| Kellogg School of Management | Masters Business Admin |
| Notre Dame University | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 4 |
| Líbano | 2 |
| España | 2 |
Operativa
| Corporate Officer/Principal | 2 |
| Masters Business Admin | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| ALTO NEUROSCIENCE, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Esteve Pharmaceuticals S.A.
Esteve Pharmaceuticals S.A. Pharmaceuticals: OtherHealth Technology Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain. | Health Technology |
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
